|
| Press Releases |
|
 |
|
| Saturday, April 29, 2017 |
|
|
Nanobiotix: 2016 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2016. more info >> |
|
| Tuesday, April 4, 2017 |
|
|
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the expansion and acceleration of its clinical development activities. more info >> |
|
| Friday, March 24, 2017 |
|
|
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results (Act.In.Sarc) of NBTXR3 in soft tissue sarcoma. more info >> |
|
| Tuesday, March 7, 2017 |
|
|
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017 |
| NANOBIOTIX today announced the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in combination with chemotherapy, in both in vitro and in vivo studies. more info >> |
|
| Tuesday, February 7, 2017 |
|
|
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO). more info >> |
|
| Wednesday, February 1, 2017 |
|
|
NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides its activities and achievements during 2016 and an overview of anticipated 2017 milestones. more info >> |
|
| Thursday, December 15, 2016 |
|
|
Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces a positive readout of initial data on the safety and feasibility from the first patients treated in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and metastatic tumors. more info >> |
|
| Tuesday, November 29, 2016 |
|
|
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides an update on the global development of its lead product, NBTXR3, across all indications. more info >> |
|
| Monday, November 14, 2016 |
|
|
Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells. more info >> |
|
| Monday, November 7, 2016 |
|
|
Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. The trial is evaluating the optimal dose, safety and preliminary efficacy of Nanobiotix's lead product. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
JDE Peet's 正式启用 OMP 的 Unison Planning(TM) 系统，大规模提升供应链价值
Apr 1, 2026 21:50 HKT/SGT
|
|
|
JDE Peet's Goes Live with OMP's Unison Planning(TM), Accelerating Supply Chain Value at Scale
Apr 1, 2026 21:50 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 21:00: JST
|
|
|
GMG Verified by Advanced Carbons Council & Successful ISO9001 Audit
Apr 1, 2026 21:00 HKT/SGT
|
|
|
Datavault AI 再度現身馬阿拉戈，出席專屬投資者論壇
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI 再度亮相马阿拉戈，参加独家投资者论坛
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 19:52: JST
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 18:52 HKT/SGT
|
|
|
True IDC Pushes "Security Economy", Breaking Ground on Mega Data Center in EEC with 77-Billion-Baht BOI Investment, Cementing Thailand's No. 1 Position
Apr 1, 2026 18:50 HKT/SGT
|
|
|
China Risun (01907.HK) Reports Strong 37.7% Net Profit Surge in 2025 Amid Industry Challenges
Apr 1, 2026 18:07 HKT/SGT
|
|
|
中國旭陽集團（01907.HK）積極面對行業變化 2025年淨利逆勢增長37.7%
Apr 1, 2026 17:50 HKT/SGT
|
|
|
中国旭阳集团（01907.HK）积极面对行业变化 2025年净利逆势增长37.7%
Apr 1, 2026 17:42 HKT/SGT
|
|
|
CTF Life Collaborates with the HKMC to Refer the Policy Reverse Mortgage Programme and the Reverse Mortgage Programme
Apr 1, 2026 16:20 HKT/SGT
|
|
|
周大福人壽與香港按揭證券有限公司合作
Apr 1, 2026 16:02 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
